Author:
Iwamuro Masaya,Tanaka Takehiro,Ennishi Daisuke,Matsueda Kazuhiro,Yoshioka Masao,Miyahara Koji,Sakaguchi Chihiro,Nishimura Mamoru,Nagahara Teruya,Mannami Tomohiko,Takenaka Ryuta,Oka Shohei,Inoue Masafumi,Takimoto Hidetaka,Inaba Tomoki,Kobayashi Sayo,Toyokawa Tatsuya,Tsugeno Hirofumi,Suzuki Seiyuu,Sawada Sachiko,Tanaka Shouichi,Tsuzuki Takao,Okada Hiroyuki
Abstract
AbstractPatients with primary intestinal follicular lymphoma are often followed-up without a specific treatment, and this approach is called the “watch-and-wait approach.” However, the long-term outcomes of this patient group have not been sufficiently investigated. We enrolled patients with primary intestinal follicular lymphoma who were diagnosed before 2016 and managed with the watch-and-wait approach in 20 institutions. We retrospectively investigated the overall, disease-specific, and event-free survival rates as well as the rate of spontaneous regression. Among the 248 patients with follicular lymphoma with gastrointestinal involvement, 124 had localized disease (stage I or II1). We analyzed the data of 73 patients who were managed using the watch-and-wait approach. During the mean follow-up period of 8.3 years, the follicular lymphoma had spontaneously resolved in 16.4% of the patients. The 5-year and 10-year overall survival rates were 92.9% and 87.1%, respectively. With disease progression (n = 7), initiation of therapy (n = 7), and histologic transformation to aggressive lymphoma (n = 0) defined as events, the 5-year and 10-year event-free survival rates were 91.1% and 86.9%, respectively. No patient died of progressive lymphoma. Thus, both 5-year and 10-year disease-specific survival rates were 100%. In conclusion, an indolent long-term clinical course was confirmed in the patients with primary intestinal follicular lymphoma. The watch-and-wait strategy is a reasonable approach for the initial management of these patients.
Publisher
Springer Science and Business Media LLC
Reference22 articles.
1. Cerhan, J. R. Epidemiology of follicular lymphoma. Hematol. Oncol. Clin. N. Am. 34, 631–646 (2020).
2. Cahill, K. E. & Smith, S. M. Follicular lymphoma: A focus on current and emerging therapies. Oncology (Williston Park) 36, 97–106 (2022).
3. Ardeshna, K. M. et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. Lancet Oncol. 15, 424–435 (2014).
4. Dreyling, M., et al. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. Suppl 3: iii76–82 (2014).
5. Harris, N.L., et al. Follicular lymphoma. In: Swerdlow, S.H., et al., editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC, 220–226 (2008).
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献